# A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Source: https://onco.cc/trials/nct05254743/  
OnCo record `nct05254743` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pirtobrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., now recruiting.

## Summary

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is a phase 3 interventional study registered as NCT05254743 by Loxo Oncology, Inc., with 737 participants planned, started 2022-07-22 and due to reach its primary completion in 2027-10. Interventions recorded: Pirtobrutinib and Ibrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05254743
- Phase: 3
- Setting: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
- Sponsor: Loxo Oncology, Inc.
- Enrolled: 737

## Sources

- ClinicalTrials.gov NCT05254743: https://clinicaltrials.gov/study/NCT05254743

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct05254743.json